Sinopharm Group Co. Ltd (X2S) — Capital Reinvestment Ratio
Sinopharm Group Co. Ltd (X2S) has a Capital Reinvestment Ratio of 0.01x as of December 2022, meaning it reinvests 0% of its operating cash flow (€52.39 Billion) in capital expenditures (€654.69 Million). Check X2S goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Sinopharm Group Co. Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks Sinopharm Group Co. Ltd's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see Sinopharm Group Co. Ltd operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for Sinopharm Group Co. Ltd from 2013 to 2025. See how much free cash does Sinopharm Group Co. Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | €14.14 Billion | €1.62 Billion | ▼ -32.9% |
| 2024 | 0.17x | €11.55 Billion | €1.97 Billion | ▲ +25.3% |
| 2023 | 0.14x | €17.17 Billion | €2.34 Billion | ▲ +34.1% |
| 2022 | 0.10x | €20.96 Billion | €2.13 Billion | ▼ -54.5% |
| 2021 | 0.22x | €9.31 Billion | €2.07 Billion | ▲ +31.0% |
| 2020 | 0.17x | €11.15 Billion | €1.90 Billion | ▲ +44.8% |
| 2019 | 0.12x | €18.78 Billion | €2.21 Billion | ▼ -86.8% |
| 2018 | 0.89x | €3.65 Billion | €3.24 Billion | ▲ +34.2% |
| 2017 | 0.66x | €3.21 Billion | €2.12 Billion | ▲ +348.6% |
| 2016 | 0.15x | €9.26 Billion | €1.36 Billion | ▲ +93.6% |
| 2015 | 0.08x | €13.41 Billion | €1.02 Billion | ▼ -70.8% |
| 2014 | 0.26x | €5.56 Billion | €1.45 Billion | ▲ +14.2% |
| 2013 | 0.23x | €4.94 Billion | €1.13 Billion | — |